Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

Ambrosini, Valentina; Tomassetti, Paola; Castellucci, Paolo; Campana, Davide; Montini, Gian Carlo; Rubello, Domenico; Nanni, Cristina; Rizzello, Anna; Franchi, Roberto; Fanti, Stefano

doi:10.1007/s00259-008-0769-2

Cited by 248 publications

(143 citation statements)

References 29 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…The method demonstrates specificity and sensitivity well above 90%, exceeding that of CT and scintigraphy (2)(3)(4). The superiority of 68 Ga-labeled somatostatin analogs in terms of specificity, sensitivity, staging accuracy, detection rate, quantification, and acquisition time over 18 F-FDG (5), 18 F-3,4-dihydroxyphenylalanine (6), 123 Imetaiodobenzylguanidine (7,8), 111 In-DTPA-pentetreotide (9), 18 F-NaF, and 99m Tc-dicarboxypropanediphosphonate (10) has been demonstrated. The high impact of 68 Ga PET/CT on patient management can be illustrated by the fact that the course of treatments was changed or adjusted in 50%-60% of cases on the basis of 68 Ga PET/CT results (11)(12)(13)(14)(15).…”

mentioning

confidence: 99%

Quantitative and Qualitative Intrapatient Comparison of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Net Uptake Rate for Accurate Quantification

et al. 2013

View full text Add to dashboard Cite

Quantitative imaging and dosimetry are crucial for individualized treatment during peptide receptor radionuclide therapy (PRRT). 177 Lu-DOTATATE and 68 Ga-DOTATOC/ 68 Ga-DOTATATE are used, respectively, for PRRT and PET examinations targeting somatostatin receptors (SSTRs) in patients affected by neuroendocrine tumors. The aim of the study was to quantitatively and qualitatively compare the performance of 68 Ga-DOTATOC and 68 Ga-DOTATATE in the context of subsequent PRRT with 177 Lu-DOTATATE under standardized conditions in the same patient as well as to investigate the sufficiency of standardized uptake value (SUV) for estimation of SSTR expression. Methods: Ten patients with metastatic neuroendocrine tumors underwent one 45-min dynamic and 3 whole-body PET/CT examinations at 1, 2, and 3 h after injection with both tracers. The number of detected lesions, SUVs in lesions and normal tissue, total functional tumor volume, and SSTR volume (functional tumor volume multiplied by mean SUV) were investigated for each time point. Net uptake rate (K i ) was calculated according to the Patlak method for 3 tumors per patient. Results: There were no significant differences in lesion count, lesion SUV, K i , functional tumor volume, or SSTR volume between 68 Ga-DOTATOC and 68 Ga-DOTATATE at any time point. The detection rate was similar, although with differences for single lesions in occasional patients. For healthy organs, marginally higher uptake of 68 Ga-DOTATATE was observed in kidneys, bone marrow, and liver at 1 h. 68 Ga-DOTATOC uptake was higher in mediastinal blood pool at the 1-h time point (P 5 0.018). The tumor-toliver ratio was marginally higher for 68 Ga-DOTATOC at the 3-h time point (P 5 0.037). Blood clearance was fast and similar for both tracers. SUV did not correlate with K i linearly and achieved saturation for a K i of greater than 0.2 mL/cm 3 /min, corresponding to an SUV of more than 25. Conclusion: 68 Ga-DOTATOC and 68 Ga-DOTATATE are suited equally well for staging and patient selection for PRRT with 177 Lu-DOTATATE. However, the slight difference in the healthy organ distribution and excretion may render 68 Ga-DOTATATE preferable. SUV did not correlate linearly with K i and thus may not reflect the SSTR density accurately at its higher values, whereas K i might be the outcome measure of choice for quantification of SSTR density and assessment of treatment outcome.

show abstract

mentioning

confidence: 99%

Quantitative and Qualitative Intrapatient Comparison of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Net Uptake Rate for Accurate Quantification

et al. 2013

View full text Add to dashboard Cite

show abstract

“…FDOPA akciğerde karsinoid tümörünün görüntülenmesi, nöroendokrin bileşen içeren akciğer nodüllerinin belirlenmesi ve tedaviye yanıtın değerlendirilmesi için kullanılmıştır (80,81). Ancak günümüzde nöroendokrin tümörlerin PET ile görüntülenmesi için daha yaygın olarak bu hücrelerin hücre zarındaki somatostatin reseptörlerine bağlanan galyum-68 (Ga-68) DOTA ile işaretli somatostatin analogları kullanılmaktadır.…”

Section: Yeni Pet Radyofarmasötikleriunclassified

Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Diagnosis and Staging of Lung Cancer

Akdemir¹,

Aydos²

2018

Nts

View full text Add to dashboard Cite

GirişAkciğer kanseri, en sık görülen kanser türlerinden biri olup, tedavi olanaklarındaki iyileşmelere rağmen kansere bağlı ölüm nedenleri arasında birinci sırada yer alır (1). Tüm akciğer kanserlerinin yaklaşık %85'ini küçük hücreli dışı akciğer kanseri (KHDAK), kalan kısmını da küçük hücreli akciğer kanseri (KHAK) oluşturur (2).KHAK hastalarının çoğunda tanı anında uzak metastaz bulunması ve bu hastaların cerrahi tedavi olasılıklarının düşük olması; buna karşılık KHDAK hastalarında cerrahi tedavi olasılığının daha yüksek olması nedeniyle bu sınıflama özellikle tedavi yaklaşımı bakımından önem taşır. Akciğer kanseri tanısı alan hastalarda uygun tedavi seçeneğini belirlemek ve hasta prognozunu Flor-18 ile işaretli florodeoksiglikoz (FDG) ile yapılan pozitron emisyon tomografisi/bilgisayarlı tomografi (PET/ BT) akciğerde kuşkulu parankimal nodülü olan veya akciğer kanseri tanısı alan hastaların klinik yönetiminde kullanılan güçlü bir tanı aracıdır. Bu yazıda FDG PET/BT görüntülemenin kuşkulu akciğer nodüllerinin değerlendirilmesinde ve yeni tanı akciğer kanserinde evrelemesindeki yerinden, sayısal PET değişkenlerinin hasta prognozu ile ilişkisinden, hibrid PET/manyetik rezonans sistemi gibi teknik gelişmelerden ve akciğer kanserinin patofizyolojisi ile ilişkili FDG dışındaki diğer PET radyofarmasötiklerinin kullanımından bahsedilmektedir. Anahtar Kelimeler: Akciğer kanseri, küçük hücreli-dışı akciğer kanseri, küçük hücreli akciğer kanseri, FDG, PET/BT görüntüleme Positron emission tomography/computed tomography (PET/ CT) using fluorine-18 labelled fluorodeoxyglucose (FDG) is a powerful tool for managing patients with suspected lung nodules and lung cancer. In this review, we discuss the utility of FDG PET/CT imaging in evaluation of suspected pulmonary nodules and initial staging of patients with newly diagnosed lung cancer, prognostic value of quantitative PET parameters, technical developments in PET imaging such as hybrid PET/ magnetic resonance systems, and the use of other PET radiopharmaceuticals related to lung cancer pathophysiology.

show abstract

“…It can be used in some cases of non-NET, if treatment with radiolabeled therapeutic SST analogs is considered. Ga-68 DOTA peptides imaging can be used in NET to localize primary tumors, staging, restaging, recurrence detection 4,[13][14][15][16][17][18][19][23][24][25] monitor the response to therapy, 26 to determine SSTR status to select the patients for SSTR radionuclide therapy. 26,27 In the present study, Ga-68 DOTATATE PET scan was positive in 23/39 (59%) patients referred for characterization or diagnosis, in 6/19 (31.5%) patients for localization, in 13/24 (54%) patients for detection of unknown NET primary, in 16/17 (94%) patients for staging, in 6/7 (85%) patients for recurrence assessment, 12/12 (100%) patients for response evaluation and 7/18 (38.8%) patients in restaging.…”

Section: Discussionmentioning

confidence: 99%

Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience

Bhansali¹,

Bhattacharya²,

Sood³

et al. 2013

Journal of Postgraduate Medicine, Education and Research

View full text Add to dashboard Cite

Introduction: Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, majority of which express somatostatin (SST) receptors. Recently, with the widespread use of positron emission tomography/computed tomography (PET/CT) and development of novel PET tracers like Ga-68 DOTA peptide which specifically bind to somatostatin receptors (SSTR), Ga-68 DOTA peptide PET/CT is used in management of NET.

show abstract

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

Abstract: Although the patients studied are few and heterogeneous, our data show that (68)Ga-DOTA-NOC is accurate for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours in either the primary or metastatic site and that it offers several advantages over (18)F-DOPA.

Cited by 248 publications

References 29 publications

Quantitative and Qualitative Intrapatient Comparison of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Net Uptake Rate for Accurate Quantification

Quantitative and Qualitative Intrapatient Comparison of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Net Uptake Rate for Accurate Quantification

Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Diagnosis and Staging of Lung Cancer

Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience

Contact Info

Product

Resources

About

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

Abstract: Although the patients studied are few and heterogeneous, our data show that (68)Ga-DOTA-NOC is accurate for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours in either the primary or metastatic site and that it offers several advantages over (18)F-DOPA.

Cited by 248 publications

References 29 publications

Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification

Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification

Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Diagnosis and Staging of Lung Cancer

Ga-68 DOTATATE PET/CT in Neuroendocrine Tumors: Initial Experience

Contact Info

Product

Resources

About

Quantitative and Qualitative Intrapatient Comparison of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Net Uptake Rate for Accurate Quantification

Quantitative and Qualitative Intrapatient Comparison of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Net Uptake Rate for Accurate Quantification